The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.
Irene Brana
No relevant relationships to disclose
Jhanelle Elaine Gray
No relevant relationships to disclose
Paul Haluska
Consultant or Advisory Role - Merck (U)
Research Funding - Merck
Raanan Berger
Consultant or Advisory Role - advisory board (U)
Talia Golan
Consultant or Advisory Role - advisory board (U)
Mary Elizabeth Jones
Employment or Leadership Position - Merck
Stock Ownership - Merck
Alexandra Gunchenko
Employment or Leadership Position - Merck
Stock Ownership - Merck
Jonathan D. Cheng
Employment or Leadership Position - Merck
Stock Ownership - Merck
Research Funding - Merck
Lillian L. Siu
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche/Genentech